Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.420
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
1.420
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Akebia Therapeutics Revenue
In the year 2025, Akebia Therapeutics had annual revenue of $236.20M with 47.46% growth. Akebia Therapeutics had revenue of $57.62M in the quarter ending December 31, 2025, with 23.93% growth.
Revenue (ttm)
$236.20M
Revenue Growth
+47.46%
P/S Ratio
1.60
Revenue / Employee
$1,217,505
Employees
194
Market Cap
380.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 236.20M | 76.02M | 47.46% |
| Dec 31, 2024 | 160.18M | -34.44M | -17.70% |
| Dec 31, 2023 | 194.62M | -97.86M | -33.46% |
| Dec 31, 2022 | 292.48M | 80.83M | 38.19% |
| Dec 31, 2021 | 211.65M | -82.99M | -28.17% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Emergent BioSolutions | 742.90M |
| Organogenesis Holdings | 564.17M |
| Esperion Therapeutics | 403.14M |
| Evolus | 297.18M |
| Ironwood Pharmaceuticals | 296.15M |
| Canopy Growth | 203.04M |
| Kamada | 180.46M |
| Anika Therapeutics | 112.82M |
AKBA News
- 15 days ago - Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 - GlobeNewsWire
- 21 days ago - Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium - GlobeNewsWire
- 26 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - Akebia Therapeutics Transcript: R&D Day 2026 - Transcripts
- 27 days ago - Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors - GlobeNewsWire
- 5 weeks ago - Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 - GlobeNewsWire
- 7 weeks ago - Akebia Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire